¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tissue thromboplastin inhibition test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® connective tissue ÇÑ±Û °áÇÕÁ¶Á÷
¼³¸í   
  Ã¼³»¿¡ ³Î¸® ºÐÆ÷Çϸç, Àå±â, Á¶Á÷»çÀ̸¦ ¸Þ¿ì°í ±×°ÍÀ» ±â°èÀûÀ¸·Î ÁöÁö, Á¶Á÷ÀÌ´Ù. ±×¹Û¿¡ Ç÷°ü, ¸²ÇÁ°ü, ½Å°æÀ» ÀεµÇϸ砿µ¾ç, ´ë»ç»ê¹°ÀÇ ¼ö¼Û ¶Ç´Â Àú·ù, ³ª¾Æ°¡¼­´Â ¼Õ»ó, °¨¿°¿¡ ´ëÇÑ ¹æ¾î ¶Ç´Â ¼öº¹ µî¿¡µµ ÀÛ¿ëÇÑ´Ù. °áÇÕÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀ̠dzºÎÇϸç, ¼¼Æ÷°£ÁúÀ» ±¸¼ºÇϴ ±âÁú°ú ¼¶À¯ÀÇ ¼º»ó¿¡ µû¶ó °£¿±Á¶Á÷, ¼¶À¯¼º °áÇÕÁ¶Á÷(¼º±ä¼¶À¯¼º °áÇÕÁ¶Á÷, ÃÎÃÎÇÑ ¼¶À¯¼º °áÇÕÁ¶Á÷), Áö¹æÁ¶Á÷, Åº¼ºÁ¶Á÷, ¼¼¸Á Á¶Á÷ µîÀ¸·Î ºÐ·ùµÈ´Ù.
  
  
¿µ¹® osseous tissue ÇÑ±Û »ÀÁ¶Á÷, °ñÁ¶Á÷
¼³¸í   
  °ñ¼¼Æ÷¿Í °ñ¼¼Æ÷ÁÖÀ§ÀÇ µüµüÇÑ Ä®½·Á¶Á÷À¸·Î µÑ·¯½ÎÀΠ¹ÐÁýµÈ °áÇÕÁ¶Á÷À» ¶æÇÑ´Ù. ÀÌ °ñÁ¶Á÷¿¡ ÀÇÇØ¼­ »À°¡ ÀÌ·ç¾îÁ® ÀÎüÀÇ °ñ°ÝÀ» Çü¼ºÇÑ´Ù.
¿µ¹® epithelial tissue ÇÑ±Û »óÇÇÁ¶Á÷
¼³¸í   
  »óÇǴ ÇÑ Ãþ ¶Ç´Â ¿©·¯ ÃþÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁø ÆÇ ¸ð¾çÀÇ ±¸Á¶·Î ½ÅüÀǠǥ¸é°ú °ü»ó±¸Á¶ÀÇ ³»°­À» µÑ·¯½Î°í ÀÖ´Ù. »óÇǼ¼Æ÷¿Í »óÇǼ¼Æ÷»çÀÌÀÇ ÀûÀº ¾çÀ¸·Î Á¸ÀçÇÏ¿© »óÇÇ»çÀÌÀÇ °ø°£À» Ã¤¿ì°í Àִ ¼¼Æ÷°£ÁúÀ» ÇÕÃÄ »óÇÇÁ¶Á÷À̶ó ÇÑ´Ù. »óÇÇÁ¶Á÷¿¡´Â ¿øÄ¢ÀûÀ¸·Î Ç÷°üÀÌ ºÐÆ÷µÇ¾î ÀÖÁö ¾Ê´Ù.
¿µ¹® granulation tissue ÇÑ±Û À°¾ÆÁ¶Á÷
¼³¸í   
  ¸ð¼¼Ç÷°üÀ̠dzºÎÇϸ砿ռºÇϰԠÁõ½ÄÀ» °è¼ÓÇϴ ¾î¸° °áÇÕÁ¶Á÷. Ã¢»ó µî Á¶Á÷ °á¼Õ¿¡ ´ëÇÑ ¼öº¹, À̹°Ã³¸®ÀÇ ±âÁúÈ­, ¿°ÁõÀÌ ¸¸¼ºÀûÀΠ°æ°ú¿¡ Àְųª Á¾¾çÁõ½Ä¿¡ µ¿¹ÝµÈ »çÀ̹°ÁúÀÇ ¹ÝÀÀ¼º ¿°Áõ¿¡¼­ °üÂûµÈ´Ù. ±¸¼º¼ººÐÀº »ý±äÁö ¾ó¸¶ ¾ÈµÇ´Â ¾î¸° À°¾ÆÁ¶Á÷Àº ¼¶À¯¸ð¼¼Æ÷ÀÇ Áõ½Ä, »õ·Î »ý±ä ¸ð¼¼Ç÷°ü°ú ¿©·¯ À¯ÁÖ¼¼Æ÷ ¹× ´Ù¸¥ Áß°£¿±¼¼Æ÷(¹éÇ÷±¸, ¸²ÇÁ±¸, ÇüÁú¼¼Æ÷, Á¶Á÷±¸, ´ÜÇÙ±¸, °Å´ë¼¼Æ÷)µîÀ¸·Î ±¸¼ºµÈ´Ù. À̰ÍÀÌ ½Ã°£ÀÌ Áö³ª ±×¸®µÇ¸é, ¸ð¼¼Ç÷°ü°ú À¯ÁÖ¼¼·Î, ´Ù¸¥Á¶Á÷¼ººÐÀ» °¨¼Ò½ÃÄÑ ¸¸¼ºÈ­ÇÏ¿© ¿À·¡µÈ À°¾Æ°¡ µÇ¸ç °á±¹Àº ¼¶À¯¼¼Æ÷¿Í ¾Æ±³Áú¼¶À¯·Î ±¸¼ºµÈ ¹ÝÈçÁ¶Á÷À¸·Î º¯ÇÑ´Ù.
¿µ¹® tissue ÇÑ±Û Á¶Á÷
¼³¸í   
  Æ¯Á¤ ±¸Á¶¿Í ±â´ÉÀ» °®´Â ¼¼Æ÷ Áý´Ü. ¼¼Æ÷ »çÀÌ¿¡´Â ´Ù¼Ò°£ ¼¼Æ÷°£ÁúÀÌ µé¾î ÀÖ´Ù. ¼¼Æ÷°£Áú¿¡´Â ±Û¸®ÄÚ»ç¹Ì³ë±Û¸®Ä­, È÷µå·Ï½Ã¾ÆÆÄŸÀÌÆ®¿Í °°Àº ±âÁú°ú ¾Æ±³Áú¼¶À¯¿Í °°Àº ¼¶À¯°¡ ¹ß°ßµÈ´Ù. Á¶Á÷¼º»óÀº ±¸¼º¼¼Æ÷¿Í ¼¼Æ÷°£ÁúÀÇ Á¾·ù¿Í ¾ç¿¡ ÀÇÇØ °áÁ¤µÈ´Ù. Á¶Á÷Àº »óÇÇÁ¶Á÷, ÁöÁöÁ¶Á÷, ±ÙÀ°Á¶Á÷, ½Å°æÁ¶Á÷À¸·Î ´ëº°µÇ¸ç, »óÇÇÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀ» °ÅÀÇ °®Áö ¾ÊÀ¸¸ç, ÁöÁöÁ¶Á÷Àº °áÇÕÁ¶Á÷À̳ª »ÀÁ¶Á÷°ú °°ÀÌ ¼¼Æ÷°£ÁúÀ̠dzºÎÇÑ °ÍÀÌ ¸¹´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • international reference thromboplastin
    ±¹Á¦Âü°íÆ®·Òº¸ÇÃ¶ó½ºÆ¾
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • migration inhibition test
    À̵¿¾ïÁ¦°Ë»ç, À̵¿ÀúÁö°Ë»ç
  • antidromic inhibition
    ¿ª¹æÇâ¾ïÁ¦
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • competitive inhibition
    °æÀï¾ïÁ¦
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • thromboplastin
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • competitive inhibition
    °æÀï¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • tissue plasminogen activator
    Á¶Á÷Çö󽺹̳ë°ÕȰ¼ºÁ¦
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • tissue
    Á¶Á÷
  • adipose tissue
    Áö¹æÁ¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
  • elastic tissue
    ź·ÂÁ¶Á÷
  • erectile tissue
    ¹ß±âÁ¶Á÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • thromboplastin plasma component
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾Ç÷À强ºÐ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • international reference thromboplastin
    ±¹Á¦Âü°íÆ®·Òº¸ÇÃ¶ó½ºÆ¾
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • thromboplastin
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • colony inhibition test
    ¼¼Æ÷±ºÇü¼º¾ïÁ¦°Ë»ç, Áý¶ôÇü¼º¾ïÁ¦°Ë»ç
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • migration inhibition test
    À̵¿¾ïÁ¦°Ë»ç, À̵¿ÀúÁö°Ë»ç
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • antidromic inhibition
    (¢¡recurrent inhibition) ȸ±Í¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • International Reference Thromboplastin
    ±¹Á¦Âü°íÆ®·Òº¸ÇÃ¶ó½ºÆ¾
  • TPC=£¾thromboplastin plasma component
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾Ç÷À强ºÐ.
  • activated partial thromboplastin time
    Ȱ¼º ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • activated partial thromboplastin time =aPTT
    Ȱ¼ºÈ­ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£
  • plasma thromboplastin
    Ç÷À寮·Òº¸ÇÃ¶ó ½ºÆ¾.
  • plasma thromboplastin antecedent
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸(îñÏÌ)¹°Áú
  • plasma thromboplastin antecedent =PTA
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸¹°Áú (
  • plasma thromboplastin component =PTC
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ(¡­à÷ÝÂ
  • plasma thromboplastin component defic
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ°áÇÌ(Áõ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ.
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • HIT= hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tissue thromboplastin inhibition test
    Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tissue thromboplastin
    Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • tissue thromboplastin
    Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾.
  • thromboplastin generation test
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾»ý¼º½ÃÇè(¡­ßæà÷ãËúÐ)
  • activated partial thromboplastin time
    Ȱ¼º ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • activated partial thromboplastin time =aPTT
    Ȱ¼ºÈ­ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£
  • partial thromboplastin time =PTT
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£.
  • partial thromboplastin time=PTT
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • plasma thromboplastin
    Ç÷À寮·Òº¸ÇÃ¶ó ½ºÆ¾.
  • plasma thromboplastin antecedent
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸(îñÏÌ)¹°Áú
  • plasma thromboplastin antecedent =PTA
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸¹°Áú (
  • plasma thromboplastin antecedent deficiency
  • plasma thromboplastin component =PTC
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ(¡­à÷ÝÂ
  • plasma thromboplastin component defic
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ°áÇÌ(Áõ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ.
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Spongy bone tissue [Trabecular bone tissue]
    ÇØ¸é»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ÇØ¸é°ñÁ¶Á÷
  • Skeletal muscular tissue
    °¡·Î¹«´Ì±ÙÀ°Á¶Á÷ [»À´ë±ÙÀ°Á¶Á÷]
    [¿¾ ¿ë¾î] °ñ°Ý±ÙÁ¶Á÷
  • Brown fat tissue
    °¥»öÁö¹æÁ¶Á÷
    [¿¾ ¿ë¾î] °¥»öÁö¹æÁ¶Á÷
  • Subconjunctival tissue
    °á¸·¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] °á¸·ÇÏÁ¶Á÷
  • Lymphoblastic tissue
    ¸²ÇÁ°ü¹ß»ýÁ¶Á÷
    [¿¾ ¿ë¾î] ÀÓÆÄ¸ð¼¼Æ÷Á¶Á÷
  • Smooth musclular tissue
    ¹Î¹«´Ì±ÙÀ°Á¶Á÷ [³»Àå±ÙÀ°Á¶Á÷]
    [¿¾ ¿ë¾î] ÆòȰ±ÙÁ¶Á÷
  • White fat tissue
    ¹é»öÁö¹æÁ¶Á÷
    [¿¾ ¿ë¾î] ¹é»öÁö¹æÁ¶Á÷
  • Loose collagenous connective tissue
    ¼º±ä¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼Ò¼º°áÇÕÁ¶Á÷
  • Reticular connective tissue
    ¼¼¸Á°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼¸Á°áÇÕÁ¶Á÷
  • Reticular tissue
    ¼¼¸ÁÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼¸ÁÁ¶Á÷
  • Cellular connective tissue
    ¼¼Æ÷¼º°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼Æ÷¼º°áÇÕÁ¶Á÷
  • Neural crest tissue
    ½Å°æ´É¼±Á¶Á÷
    [¿¾ ¿ë¾î] ½Å°æ¸ªÁ¶Á÷
  • Tissue of neural crest (Mesectoderm)
    ½Å°æ´É¼±Á¶Á÷ (Áß°£¿Ü¹è¿±)
    [¿¾ ¿ë¾î] ½Å°æ¸ªÁ¶Á÷
  • Nervous tissue (Neuroblastoma)
    ½Å°æÁ¶Á÷ (½Å°æ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½Å°æÁ¶Á÷
  • Cardiac muscular tissue
    ½ÉÀå±ÙÀ°Á¶Á÷
    [¿¾ ¿ë¾î] ½É±ÙÁ¶Á÷
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bilharzial granulation tissue
    ¹æ±¤ÁÖÇ÷ÈíÃæÀ°¾ÆÁ¶Á÷
  • tissue parasite
    Á¶Á÷±â»ýÃæ
  • tissue selectivity
    Á¶Á÷¼±Åüº
  • Bachman intradermal test
    ¼±¸ðÃæÇdz»¹ÝÀÀ°Ë»ç
  • bentonite flocculation test
    º¥Å䳪ÀÌÆ®ÀÀÁý°Ë»ç
  • Casoni test
    Æ÷ÃæÇdz»¹ÝÀÀ°Ë»ç
  • circumoval precipitin test (COPT)
    Ãæ¶õÁÖÀ§Ä§°­°Ë»ç
  • intradermal test
    Çdz»¹ÝÀÀ°Ë»ç
  • Mazzotti test
    ¸¶Á¶Æ¼°Ë»ç
  • Montenegro test
    ¸óÅ״ϱ׷ΰ˻ç
  • Sabin-Feldman dye test
    (Åå¼ÒÆ÷ÀÚÃæ) »ö¼Ò¸é¿ª°Ë»ç
  • screening test
    ¼±º°°Ë»ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tissue thromboplastin
    Á¶Á÷(ðÚòÄ)Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • extrinsic thromboplastin
    ¿ÜÀÎ(èâì×) Æ®·Òº¸Ç÷¡½ºÆ¾
  • plasma thromboplastin antecedent
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ Àü±¸¹°(îñÏÌÚª)
  • plasma thromboplastin component
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ¼ººÐ(à÷ÝÂ)
  • thromboplastin
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ)
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ½ÃÇè(ãËúÐ)
  • adipose tissue
    Áö¹æÁ¶Á÷(ò·Û¸ðÚòÄ)
  • brown adipose tissue
    °¥»öÁö¹æÁ¶Á÷(Êèßäò·Û¸ðÚòÄ)
  • established tissue chluture
    ¼ö¸³ Á¶Á÷¹è¾ç (â§Ø¡ðÚòÄÛÆå×)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • primary tissue culture
    ÀÏÂ÷ Á¶Á÷¹è¾ç(ìéó­ðÚòÄÛÆå×)
  • tissue culture
    Á¶Á÷¹è¾ç (ðÚòÄÛÆå×)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
  • pelvis perfusion test(Whitaker test)
    ½Å¿ì°ü·ù°Ë»ç
  • arm to lung time test
    ÆÈÆó¼øÈ¯½Ã°£½ÃÇè
  • chi-square test
    Ä«ÀÌÁ¦°ö°ËÁ¤
  • complement fixation test
    º¸Ã¼°áÇÕ½ÃÇè
  • contraction test
    ¼öÃà°Ë»ç
  • double blind test
    ÀÌÁ߸Ͱ˹ý
  • dye dilution test
    »ö¼ÒÈñ¼®½ÃÇè
  • guaiac test
    °úÀ̾׽ÃÇè
  • laboratory test
    °Ë»ç
  • pivot shift test
    ÃßÃà º¯À§½ÃÇè
  • provocation test
    À¯¹ß½ÃÇè
  • provocative test
    À¯¹ß½ÃÇè
  • pulmonary function test
    Æó±â´É°Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TAT tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex...
RI radiation intensity; radioactive isotope; radioimmunology; recession index; recombinant inbred [stra...
TST thiosulfate sulfur-transferase; thromboplastin screening test; total sleep time; transforming sequen...
IT immunological test; immunotherapy; implantation test; individual therapy; information technology; in...
PAT Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
APTT Activated Partial Thromboplastin Time
APTT Activated partial thromboplastin
aPTT Partial thromboplastin time
TP thromboplastin
HI Haemagglutination inhibition test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • thromboplastin generation test
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾ »ý¼º ½ÃÇè
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • complement fixation inhibition test
    º¸Ã¼ °íÁ¤ ÀúÇØ ½ÃÇè
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ ½ÃÇè
    Ç×üÀÇ Ç׿ø Ư¼ö °áÇÕ ºÎÀ§¸¦ µ¤´Â ÇÕÅÙÀ» ÀÌ¿ëÇÏ¿© Ç׿ø °áÁ¤±âÀÇ Ç÷ûÇÐÀû Ư¼ºÀ» °Ë»çÇÏ´Â ½ÃÇè.
  • hemagglutination inhibition test
    ÀûÇ÷±¸ ÀÀÁý ¾ïÁ¦ ½ÃÇè
  • allogeneic inhibition
    µ¿Á¾ ÀÌÇü ¾ïÁ¦
  • antagonistic inhibition
    ±æÇ×±Ù ¾ïÁ¦, ±æÇ×Àû ¾ïÁ¦, ±æÇ×Àû ÀúÇØ
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦
    ¾î¶² ¼ö¿ëü¿¡ ´ëÇØ °áÇÕ·ÂÀÌ Å« ¹°ÁúÀÌ »ó´ëÀûÀ¸·Î °áÇÕ·ÂÀÌ ¾àÇÑ ´Ù¸¥ ¹°ÁúÀÇ °áÇÕÀ» ¾ïÁ¦ÇÏ´Â °Í.
  • cyto- ¼¼Æ÷¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    cyto-inhibition

    ¼¼Æ÷ ¾ïÁ¦ ÀÛ¿ë
    ޽ÄÇÑ ¼¼±Õ ¶Ç´Â ¹ÙÀÌ·¯½º¸¦ ¿ëÇØÇϰųª È­Çпä¹ýÁ¦¿¡ ÀÇÇÑ È­ÇÐÀû ÆÄ±«·ÎºÎÅÍ ¹æ¾îÇÏ´Â ½Ä ¼¼Æ÷ÀÇ ÀÛ¿ë.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
    °úÁ¤ÀÇ ¾ï¾Ð
  • inhibition reaction
    ¾ïÁ¦, ¾ïÁ¦ ¹ÝÀÀ, ÀúÁö, ÀúÁö ¹ÝÀÀ
  • inhibition zone
    ¾ïÁ¦´ë
    ħ°­ ¶Ç´Â ÀÀÁý ¹ÝÀÀ¿¡¼­ Ç×ü ³óµµ°¡ ³ôÀº Ç÷û¿¡¼­´Â Ç׿ø ÀÔÀÚ¿Í ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê´Â Çö»ó.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
tissue thromboplastin inhibition time A test used to identify lupus anticoagulant; the thromboplastin source used in the prothrombin test is diluted to increase sensitivity to inhibitors.
(05 Mar 2000)
activated partial thromboplastin time The time needed for plasma to form a fibrin clot following the addition of calcium and a phospholipid reagent; used to evaluate the intrinsic clotting system.
(05 Mar 2000)
partial thromboplastin time Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy.
(12 Dec 1998)
plasma thromboplastin antecedent <chemical> Stable blood coagulation factor involved in the intrinsic pathway. The activated form xia activates factor ix to ixa. Deficiency of factor xi is often called haemophilia c.
Chemical name: Blood-coagulation factor XI
(12 Dec 1998)
plasma thromboplastin component <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
plasma thromboplastin factor A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
plasma thromboplastin factor B <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
thromboplastin <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin).
(18 Nov 1997)
macrophage migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
haemagglutination inhibition test <investigation> A clinical lab test used to detect the presence of a certain haemagglutinating virus or other haemagglutinin antigen based on whether the red blood cells in the sample lose the ability to clump together when the antibody to the virus or other antigen is added to it.
If the virus or antigen is present, the antibody kills it and thereby stops it from being able to stick the red blood cells to each other.
(09 Oct 1997)
leukocyte adherence inhibition test Test for cell-mediated antitumour immunity and related serum blocking factors based on the finding that leukocytes from cancer patients, but not from controls, when mixed in vitro with antigenic extracts of tumours of the same histological type, undergo a diminution in their normal adherence to glass surfaces. Sera from tumour-bearing patients block the lai reaction of their own leukocytes or those of other patients with the same type of tumour.
(12 Dec 1998)
allogeneic inhibition Inhibition or injury to allogeneic cells that occurs when lymphocytes are mixed and cultured with other cells of different genotypes in vitro.
(05 Mar 2000)
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦
  • feedback inhibition
    Çǵå¹é ÀúÇØ
  • inhibition
    ±ÝÁö;±ÝÁ¦;¾ïÁ¦;¾ï¾Ð;(¿µ±¹±³)¼º¹«ÁýÇà±ÝÁö¸í·É;(¿µ¹ý)¼Ò¼ÛÁøÇàÁ¤Áö¿µÀå
  • tissue
    Á¶Á÷
  • cleansing tissue
    È­Àå¿ë ¹Ú¿±Áö(Ƽ½´ ÆäÀÌÆÛ)
  • connective tissue
    °áÇÕ Á¶Á÷
  • facial tissue
    °í±Þ È­ÀåÁö
  • permanent tissue
    ¿µ±¸ Á¶Á÷
  • tissue
    Á¶Á÷;¾ãÀº Á÷¹°;(°ÅÁþ¸» µûÀ§ÀÇ)µÚ¹ü¹÷;¿¬¼Ó;ź¼Ò ÀÎÈ­Áö
  • test
    ½ÃÇè,½ÃÇèÇÏ´Ù
  • Binet Simon test
    Áö³×½Ã¸ù½Ä Áö´É °Ë»ç¹ý
  • Dick test
    (ÀÇ)µñ Å×½ºÆ®(¼ºÈ«¿­ ÇǺΠ½ÃÇè)
  • Kline test
    Ŭ¶óÀÎ ½ÃÇè(¸Åµ¶ Ç÷ûÀÇ Ä§°­ ¹ÝÀÀ)
  • New Test.
    New Testament
  • Partial Test Ban Treaty
    ºÎºÐÀû ÇÙ½ÇÇè ±ÝÁö Á¶¾à
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á